Study Results, Private Placements, Collaborations, Product Launches, and Public Offerings - Research Report on ViroPharma, Incyte, Tenet Healthcare, Sagent Pharmaceuticals and Chelsea Therapeutics

NEW YORK, November 22, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting ViroPharma Inc. (NASDAQ: VPHM), Incyte Corporation (NASDAQ: INCY), Tenet Healthcare Corp. (NYSE: THC), Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

ViroPharma Inc. Research Report

On November 12, 2013, ViroPharma Inc. (ViroPharma) announced results of a new quality of life data analysis from the randomized, placebo-controlled pivotal prophylaxis study of Cinryze (C1 esterase inhibitor [human]), the first and only C1 esterase inhibitor therapy approved for routine prevention of angioedema attacks in patients with HAE. ViroPharma informed that the data was presented in a poster entitled: Quality of Life in Patients with Hereditary Angioedema Receiving Nanofiltered C1 Inhibitor for Prophylaxis: Results of a Randomized, Placebo-Controlled, Crossover Study, by William Lumry, MD, FAAAI, FACAAI, et al at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting. Lead author and Medical Director of Asthma and Allergy Research Associates in Dallas, Texas, Dr. William Lumry said, "These data demonstrate that patients who received prophylaxis with C1 inhibitor had significantly better quality of life compared to acute therapy with C1 inhibitor while on placebo. The analysis underscores the importance of educating patients on the potential benefits of prevention, and that prevention should be considered by physicians among the therapeutic options for patients with hereditary angioedema." The Full Research Report on ViroPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c730_VPHM

--

Incyte Corporation Research Report

On November 14, 2013, Incyte Corporation (Incyte) announced the completion of its previously announced private placement of $750 million aggregate principal amount of its convertible senior notes, including notes which were issued upon the exercise in full of the initial purchasers' option to purchase additional notes. The Company stated that it issued $375 million aggregate principal amount of 0.375% convertible senior notes due 2018 and $375 million aggregate principal amount of 1.25% convertible senior notes due 2020. Incyte stated that entities affiliated with Julian C. Baker, a director of the Company, purchased $500 million aggregate principal amount of notes in this offering, consisting of $250 million aggregate principal amount of the 2018 notes and $250 million aggregate principal amount of the 2020 notes. The Company informed that it used a portion of the net proceeds from this offering to repurchase a portion of the outstanding 4.75% convertible senior notes due 2015 of the Company held by entities affiliated with Mr. Baker, in privately negotiated transactions, for an aggregate consideration, including accrued interest, of approximately $500 million. The Company also stated that it intends to use the remainder of the net proceeds from this offering to continue its investment in research and development, and for other general corporate purposes. The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/076e_INCY

--

Tenet Healthcare Corp. Research Report

On November 12, 2013, Tenet Healthcare Corp. (Tenet) reported that Blue Cross and Blue Shield of Texas and Tenet have agreed to collaborate to offer an innovative, statewide accountable care organization (ACO) model to deliver improved, sustainable patient care and help manage costs through Tenet's Integrated Care Networks. The Company stated that the said collaboration is intended to be available to BCBSTX PPO commercial patients at any of Tenet's Texas hospitals with an Integrated Care Network starting January 1, 2015. Tenet informed that the agreement may be expanded to include health insurance marketplace patients over the life of the agreement. According to Tenet, the new model of healthcare delivery is designed to improve outcomes in three key categories: quality of care, patient experience and satisfaction and cost efficiency. The Full Research Report on Tenet Healthcare Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1d25_THC

--

Sagent Pharmaceuticals, Inc. Research Report

On November 18, 2013, Sagent Pharmaceuticals, Inc. (Sagent Pharmaceuticals) announced the launch of Propofol Injectable Emulsion USP 1%, in two Single-Dose, Single-Patient vial presentations of 20 mL and 100 mL. The Company informed that a 50 mL Single-Dose, Single-Patient vial presentation will be released briefly. Sagent Pharmaceuticals stated that according to IMS, the US market for Propofol was approximately $230 million for the 12 months ended September 2013. The Full Research Report on Sagent Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a901_SGNT

--

Chelsea Therapeutics International Ltd. Research Report

On November 18, 2013, Chelsea Therapeutics International Ltd. (Chelsea Therapeutics) announced that it has completed its previously announced public offering of c.7.7 million shares of its common stock, including 1 million shares of common stock that were issued upon exercise in full of the over-allotment option granted to the underwriters. The Company stated that this would increase the net proceeds to the Company from approximately $18.6 million to approximately $21.4 million, after underwriting discounts and commissions and expenses. Chelsea Therapeutics informed that it intends to use the net proceeds from this offering to fund its droxidopa program, including regulatory and possible initial commercialization activity for Northera, and for general corporate purposes. The Full Research Report on Chelsea Therapeutics International Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c6ad_CHTP

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected]rk.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner